DURHAM, NC – September 7, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid tumors, today announced the company will participate in the following two virtual investment conferences taking place in September 2021: Event:…
DURHAM, NC – August 17, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapy platforms for the treatment of solid tumors, today announced the company is proceeding with the expansion of its LUMINOS-103 trial, with a…
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma DURHAM, NC – Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapy platforms for the treatment of solid tumors, announced today the U.S.…
Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team Istari Oncology, Inc., a clinical-stage biotechnology company today announced that Jamie Iudica has joined as Chief Manufacturing Officer (CMO). Iudica brings more than 25 years…
Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting LUMINOS-101 and LUMINOS-102 study designs to be presented Preclinical data for PVSRIPO in combination with anti-PD-1 immune checkpoint inhibitors…
Istari Oncology Honored as "Best Early Stage Product Development Company" in the Triangle Business Journal's Life Sciences Awards Raleigh, NC, May 20, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company focused on novel immunotherapies for the treatment of solid…
Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma Objective responses observed in patients’ refractory to programmed death receptor-1 (PD-1) inhibitors and BRAF-targeted therapy Responses in both injected and…
Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors Istari clinical trial program expands to evaluate PVSRIPO in a range of solid tumors…
Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO LUMINOS-101 and LUMINOS-103 study designs to be presented Expanding clinical trial program designed to…
Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma DURHAM, NC, March 31, 2021 – Istari Oncology, Inc., a clinical-stage biotechnology company, today…